Articles
Latest research explainers
Long-form breakdowns on mechanism, comparisons and safety.
Modalert, Modvigil, Waklert and Artvigil compared: reported consistency, purity and why generics feel different.
What community reports say about vendor delivery, dispute resolution and product authenticity, and the limits of that data.
Starting doses, why 50-75 mg often does nothing, and what the evidence says about switching to armodafinil.
Reported at 10-30% incidence: the proposed histaminergic, cholinergic and vascular mechanisms, and what actually helps.
How the de minimis closure disrupted international shipping, and what domestic vendors trade in cost for predictability.
Mood-elevating in some, anxiogenic in others: what trials, case reports and meta-analyses actually document.
Approved indications, starting doses, and the pharmacokinetic reasons behind a start-low, go-slow approach.
Half-life, clearance estimates, immunoassay cutoffs and why detection windows are ranges rather than fixed numbers.